T1	Participants 423 646	RA patients of Shen deficiency and cold invading syndrome in the treatment group (120 cases) were treated with BQZD and MTX (10 mg/week), while those in the control group (120 cases) were treated with MTX (10 mg/week) alone
T2	Participants 1113 1227	0% in the treatment group, better than that of the control group (66.7%), showing statistical difference (P <0.01)
T3	Participants 1229 1246	In the two groups
T4	Participants 1499 1514	treatment group
T5	Participants 1603 1611	patients
T6	Participants 1719 1760	treatment group than in the control group
